Phaseline

Companies › Rare Thyroid Therapeutics International

Rare Thyroid Therapeutics International: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tiratricol
Thyroid hormone receptor agonist
THRA, THRBPhase 2Allan-Herndon-Dudley SyndromeJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02396459TiratricolPhase 2Allan-Herndon-Dudley SyndromeMetabolic and endocrineJul 2027

Targets

THRA (1) THRB (1)

Companies with the same targets

AbbVie SAb Biotherapeutics Madrigal Pharmaceuticals

Companies built like this

SAb Biotherapeutics Amorphical ERX Pharmaceuticals Hyundai Pharm River 3 Renal

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.